+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Anaplastic Lymphoma Kinase Inhibitors Market Size, Market Share, Application Analysis, Regional Outlook, Growth Trends, Key Players, Competitive Strategies and Forecasts, 2021 to 2029

  • PDF Icon

    Report

  • 114 Pages
  • November 2021
  • Region: Global
  • Acute Market Reports
  • ID: 5616082

Industry Outlook


The anaplastic lymphoma kinase (ALK) inhibitors market is set to reach from US$ 2,130.8 Mn in 2020 to 11,860.6 Mn by 2029 keen to demonstrate exuberating growth at a compounded annual growth rate (CAGR) of 21.2% during the forecast period from 2021 to 2029. Lung cancer is the second most occurring type of cancer in both men and women population worldwide. Increased consumption of tobacco, unhealthy lifestyle and stress are the major risk factor responsible for the occurrence of lung cancer. A strong drug pipeline of second and third generation ALK inhibitors being currently studied in various stages of clinical trials are being developed specifically for the treatment of non small cell lung cancer (NSCLC).

Excellent pharmacodynamic and pharmacokinetic properties drive the market growth of first generation ALK inhibitors


Non small cell lung cancer (NSCLC) is the most common type of lung cancer occurring throughout the globe. The prognosis of the NSCLC is difficult and its initial screening is rather poor which significantly increases the requirement for development of targeted drug therapy for its treatment. FDA has approved only 2 drugs specifically for the treatment of NSCLC In the present scenario first generation ALK inhibitor Crizotinib is spearheading the molecule segment for anaplastic lymphoma kinase inhibitors market. It is basically an aminopyridine and piperidine derivative which selectively inhibits receptor tyrosine kinase and the ALK fusion proteins during the treatment of NSCLC. It has the potency to inhibit tumor cell growth. Alectinib hydrochloride is another first line ALK inhibitor which effectively inhibits wild type ALK point mutant variants and disrupts the tumor cell growth associated with advanced stage NSCLC. Hence, excellent pharmacodynamic and pharmacokinetic properties together drive the market growth for first generation ALK inhibitors.

Rising prevalence of lung cancer and affordable reimbursement scenario together drive the market growth in North America region


Representing a share of 36.2% North America is currently leading the regional segment for anaplastic lymphoma kinase (ALK) inhibitors market. According to the research findings of American Society of Clinical Oncology (ASCO), in 2021, approximately 228,150 U.S. citizens have been reported to be suffering with lung cancer with a high prevalence rate in African American people. Affordable reimbursement scenario pertaining to the treatment of non small cell lung cancer drives the market growth ALK inhibitors in North America region. Europe is in the second place with 29.8% market share primarily due to huge prevalence rate of lung cancer in the European Union which is 54 per 100,000 people as brought forward by the 2020 statistical report of European Commission. Supportive regulatory environment provided by the European Medical Agency to expedite the clinical trials pertaining to second and third generation anaplastic lymphoma kinase inhibitors for the treatment of non small cell lung cancer (NSCLC). Asia Pacific presently accounts for 15.5% market share and is keen to register outstanding growth during the forecast period on account of significant rise in tobacco consumption, thereby promoting the proliferation of NSCLC and developing healthcare infrastructure.

Historical & Forecast Period


This research report presents the analysis of each segment from 2019 to 2029 considering 2020 as the base year for the research. Compounded annual growth rate (CAGR) for each respective segments are calculated for the forecast period from 2021 to 2029.

Biopharmaceutical companies actively seeking to create a strong foothold in the anaplastic lymphoma kinase inhibitors market are Betta Pharmaceutcials Co., Ltd., Crtierium, Inc., F.Hoffman-La Roche Ltd., Helsinn Therapeutics, Novartis AG., Oncoethix GmbH, Pfizer, Inc., Takeda Pharmaceutical Co., Ltd., Xcovery Holding Company, LLC and Tesaro, Inc.

Key questions answered in this report

  • Which biopharmaceutical companies are engaged in the development of ALK inhibitors for the treatment of NSCLC?
  • What are the inorganic and organic market growth strategies adopted for the market assessment of anaplastic lymphoma kinase inhibitors market?
  • What is the disease etiology associated with NSCLC?
  • Why are the first line ALK inhibitors employed selectively for the treatment of NSCLC?
  • What is the prevalence rate of lung cancer in developing nation of Asia Pacific and Latin America regional segment?

Table of Contents

Chapter 1. Preface
1.1. Report Scope and Description
1.1.1. Purpose of the Report
1.1.2. Target Audience
1.1.3. USP and Key Molecule
1.2. Research Scope
1.3. Research Methodology
1.3.1. Phase I-Secondary Research
1.3.2. Phase II-Primary Research
1.3.3. Approach Adopted
1.3.4. Top-down Approach
1.3.5. Bottom-up Approach
1.3.6. Phase III-Expert Panel Review
1.3.7. Assumptions
1.4. Market Segmentation
Chapter 2. Executive Summary
2.1. Global ALKI Market Portraiture
2.2. Global ALKI Market, by Molecule, 2020 (US$ Mn)
2.3. Global ALKI Market, by Geography, 2020 (US$ Mn)
Chapter 3. Anaplastic Lymphoma Kinase Inhibitors (ALKI) Market: Dynamics and Future Outlook
3.1. Market Overview
3.2. Drivers
3.3. Challenges
3.4. Opportunities
3.5. Attractive Investment Proposition, by Geography, 2020
3.6. Competitive Analysis: Global ALKI Market, by Key Players, 2020
Chapter 4. Global Anaplastic Lymphoma Kinase Inhibitors (ALKI) Market, by Molecule
4.1. Overview
4.2. Crizotinib
4.3. Ceritniib
4.4. Alectinib hydrochloride
4.5. Pipeline Analysis
4.5.1. Tabular Representation of Phase I and II Drug Pipeline
Chapter 5. Global Anaplastic Lymphoma Kinase Inhibitors (ALKI) Market, by Geography
5.1. Overview
5.2. North America ALKI Market Analysis, 2019 - 2029
5.2.1. North America ALKI Market, by Molecule, 2019 - 2029 (US$ Mn)
5.2.2. North America ALKI Market, by Country, 2019 - 2029 (US$ Mn)
5.2.2.1. U.S.
5.2.2.2. Canada
5.3. Europe ALKI Market Analysis, 2019- 2029
5.3.1. Europe ALKI Market, by Molecule, 2019 - 2029 (US$ Mn)
5.3.2. Europe ALKI Market, by Country/Region, 2019 - 2029 (US$ Mn)
5.3.2.1. U.K.
5.3.2.2. Germany
5.3.2.3. Rest of Europe
5.4. Asia Pacific ALKI Market Analysis, 2019 - 2029
5.4.1. Asia Pacific ALKI Market, by Molecule, 2019 - 2029 (US$ Mn)
5.4.2. Asia Pacific ALKI Market, by Country/Region, 2019 - 2029 (US$ Mn)
5.4.2.1. China
5.4.2.2. Japan
5.4.2.3. Rest of Asia Pacific
5.5. Latin America ALKI Market Analysis, 2019 - 2029
5.5.1. Latin America ALKI Market, by Molecule, 2019 - 2029 (US$ Mn)
5.5.2. Latin America ALKI Market, by Country/Region, 2019 - 2029 (US$ Mn)
5.5.2.1. Brazil
5.5.2.2. Mexico
5.5.2.3. Rest of Latin America
5.6. Middle East & Africa ALKI Market Analysis, 2019 - 2029
5.6.1. MEA ALKI Market, by Molecule, 2019 - 2029 (US$ Mn)
5.6.2. MEA ALKI Market, by Region, 2019- 2029 (US$ Mn)
5.6.2.1. GCC
5.6.2.2. Rest of MEA
Chapter 6. Company Profiles
6.1. Betta Pharmaceuticals Co., Ltd.
6.1.1. Business Description
6.1.2. Financial Information (Subject to data availability)
6.1.3. Product Portfolio
6.1.4. News Coverage
6.2. Criterium, Inc.
6.3. F. Hoffman-La Roche Ltd.
6.4. Helsinn Therapeutics
6.5. Novartis AG
6.6. Oncoethix GmbH
6.7. Pfizer, Inc.
6.8. Takeda Pharmaceutical Co., Ltd.
6.9. Xcovery Holding Company, LLC
6.10. Tesaro, Inc.

Companies Mentioned

  • Betta Pharmaceutcials Co. Ltd.
  • Crtierium Inc.
  • F.Hoffman-La Roche Ltd.
  • Helsinn Therapeutics
  • Novartis AG.
  • Oncoethix GmbH
  • Pfizer Inc.
  • Takeda Pharmaceutical Co. Ltd.
  • Xcovery Holding Company LLC
  • Tesaro Inc